Edoxaban mg or 60mg daily vs Warfarin - stroke or systemic embolism

EDOXABAN MG OR 60MG DAILY VS. WARFARIN (TO MAINTAIN AN INR OF 2-3), PATIENTS WITH NON VALVULAR AF, STROKE OR SYSTEMIC EMBOLISM

Study population:

Patients with non valvular AF

Mean CHADS2 score 2.8

CHADS2 score 4-6 (23%)

Median age 72 years (range 64-78)

Comments:

This means that treating 167 patients with edoxaban instead of warfarin for 2.8 years might prevent one stroke or systemic embolism, and treating 67 patients with edoxaban instead of warfarin for 2.8 years might prevent one major bleeding episode. Note, however, that the warfarin group were within therapeutic range only 68% of the time.

30mg daily  licensed if:

CrCl 15 - 50 ml/min or

body weight ≤ 60 kg or

concomitant ciclosporin, dronedarone, erythromycin, or ketoconazole

NNH, with respect to major bleeding, 67